Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib

Molina, Ana; Ginsberg, Michelle; Motzer, Robert; Molina, Ana M; Ginsberg, Michelle S; Motzer, Robert J
December 2011
Medical Oncology;Dec2011, Vol. 28 Issue 4, p1527
Academic Journal
journal article
A 70-year-old man with metastatic renal cell carcinoma developed progressive liver metastases after 8 weeks of treatment with the multitargeted tyrosine kinase inhibitor (TKI) sunitinib. He then participated in the phase III placebo-controlled clinical trial of the oral mammalian target of rapamycin (mTOR) inhibitor everolimus, initially randomized to placebo (but had disease progression after 3 months) and crossed over to everolimus at time of unblinding. The patient had stable disease after 8 weeks (two cycles) of everolimus that was maintained until 28 months of therapy, at which time the patient had achieved a partial response. This case illustrates the potential for patients with metastatic renal cell carcinoma, a malignancy with historically poor prognosis, to derive long-term benefit from everolimus when used in a manner consistent with its approved indication (after TKI therapy with sunitinib or sorafenib).


Related Articles

  • Operative Therapy in Disease Progression and Local Recurrence of Renal Cell Carcinoma. Fischer, Claus G.; Schmid, Hans-Peter // Urologia Internationalis;Jul99, Vol. 63 Issue 1, p10 

    When local recurrence or distant metastasis occurs, the question arises as to which therapeutic concept should be applied. In contrast to the data on systemic immunotherapy, there are no systematic studies on surgical management of metastasis. Local recurrence (a rare condition) is frequently...

  • Spontaneous Regression of Hepatic Metastases after Nephrectomy and Metastasectomy of Renal Cell Carcinoma. Wyczółkowski, Marek; Klima, Włodzimierz; Bieda, Witold; Walas, Krystyna // Urologia Internationalis;Feb2001, Vol. 66 Issue 2, p119 

    We report a case of clear cell carcinoma of the kidney with multifocal metastases to the lymph nodes, vagina and liver. Spontaneous regression of liver metastasis has been described after nephrectomy. Surgical management of primary and metastatic tumors should be considered in all patients with...

  • Late Local and Pulmonary Recurrence of Renal Cell Carcinoma. Froehner; Manseck; Lossnitzer; Wirth // Urologia Internationalis;May98, Vol. 60 Issue 4, p248 

    Locally recurrent renal cell carcinoma and multiple pulmonary metastases were successfully resected in a patient 20 years after nephrectomy.

  • Cutaneous Metastases in Renal Cell Carcinoma. Bujons, A.; Pascual, X.; Martínez, R.; Rodríguez, O.; Palou, J.; Villavicencio, H. // Urologia Internationalis;Jan2008, Vol. 80 Issue 1, p111 

    Cutaneous metastases from a renal cell carcinoma are rarely diagnosed during life. We report a case of renal carcinoma metastatic to the skin that occurred 18 months after kidney removal. The cutaneous metastasis was excised. Cutaneous metastases from urological tumors are uncommon and occur in...

  • Probability of Ten-Year Survival in Metastatic Renal Cell Carcinoma. Salagierski, Maciej; Salagierski, Marek; Salagierska-Barwińska, Anna; Sosnowski, Marek // Urologia Internationalis;Apr2008, Vol. 80 Issue 3, p335 

    Metastatic renal cancer has a very poor prognosis and constitutes a challenge to uro-oncologists. We present a patient who in the 10 years following the diagnosis of renal cell carcinoma developed nine consecutive metastases in as many sites. He was operated on eleven times in different...

  • New Cut-Off Point between T1 and T2 Renal Cell Carcinoma – Necessary for a Better Discriminatory Power of the TNM Classification. Wunderlich, H.; Dreihaupt, M.; Schlichter, A.; Kosmehl, H.; Reichelt, O.; Schubert, J. // Urologia Internationalis;Feb2004, Vol. 72 Issue 2, p123 

    Purpose: We evaluated the pathological features of tumor size, lymph node and distant metastases, cell type, growth pattern, infiltration pattern, histological grade, local invasion and venous involvement of organ-confined renal carcinomas. The aim of this study was the re-evaluation of the TNM...

  • Prostatic Metastasis of Renal Cell Carcinoma Successfully Treated with Sunitinib. Fokt, Ralf-Michael; Templeton, Arnoud; Gillessen, Silke; Öhlschlegel, Christian; Schmid, Hans-Peter // Urologia Internationalis;Jul2009, Vol. 83 Issue 1, p122 

    Metastases of renal cell carcinoma to the prostate gland are very rare. We present a case of a metastasis of renal cell carcinoma in the prostate which occurred 10 years after nephrectomy. Treatment with sunitinib was initiated and a notable response achieved. Copyright © 2009 S. Karger AG, Basel

  • Solitary Contralateral Adrenal Metastasis after Nephrectomy for Renal Cell Carcinoma. Moudouni; En-Nia; Rioux-Leclercq; Guille; Lobel // Urologia Internationalis;May2002, Vol. 68 Issue 4, p295 

    Malignant involvement of the contralateral adrenal gland in cases of renal cell carcinoma is extremely rare. Solitary metachronous metastatic involvement of the contralateral adrenal gland from renal cell carcinoma is rarely diagnosed during life. In fact, clinical signs and symptoms of adrenal...

  • The Use of the American Society of Anesthesiology Classification as a Prognostic Factor in Patients with Renal Cell Carcinoma. Zequi, Stênio de Cássio; de Campos, Eurico C. R.; Guimarães, Gustavo C.; Bachega Jr., Wilson; da Fonseca, Francisco P.; Lopes, Ademar // Urologia Internationalis;Feb2010, Vol. 84 Issue 1, p67 

    Objectives: We analyzed whether the American Society of Anesthesiology (ASA) classification could be used as a prognostic factor in renal cell carcinoma. Methods: ASA classification’s impact on cancer-specific survival (CSS) and on overall survival in 145 patients submitted to radical or...

  • Collecting Duct Renal Cell Carcinoma: Two Different Clinical Stages, Two Different Clinical Outcomes. Vá;zquez-Lavista, L. G.; Uribe-Uribe, N.; Gabilondo-Navarro, F. // Urologia Internationalis;Jul2008, Vol. 81 Issue 1, p116 

    Collecting duct carcinoma (CDC) of Bellini is a rare variant of renal cell carcinoma. It tends to be more aggressive when locally advanced or when having distant spread on diagnosis. The only favorable prognosis factor is low-stage, low-grade, with disease-free survival reported up to 5 years....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics